<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234607</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-Ⅲ-04</org_study_id>
    <nct_id>NCT04234607</nct_id>
  </id_info>
  <brief_title>A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)</brief_title>
  <official_title>A Randomized, Double-blind, Controlled, Multicenter Phase III Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, controlled, multicenter phase III study of TQB2450 or placebo
      combined with Anlotinib, etoposide and carboplatin versus Etoposide and Carboplatin in
      subjects with extensive small cell lung cancer. The primary outcome measures include PFS and
      OS. Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing
      the informed consent, and then centrally randomized 1:1:1 to the experimental arms and the
      control arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response（DOR）</measure>
    <time_frame>up to 12 months</time_frame>
    <description>For participants who demonstrate CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS rate of 6 and 12 months progression-free survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>PFS rate of progression-free survival at 6 and 12 months: the percentage of subjects who did not develop disease progression or die of any cause at 6 and 12 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate of 12 and 18 months total survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Total survival OS rate at 12 and 18 months: the proportion of subjects who died of any cause at 12 and 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Security Index</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">738</enrollment>
  <condition>Extensive Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TQB2450+Anlotinib+ etoposide + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induced stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQB2450（blank）+Anlotinib+ etoposide + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+ Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib (blank) capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules (blank) 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450+Anlotinib+ etoposide + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>a multi-target receptor tyrosine kinase inhibitor</description>
    <arm_group_label>TQB2450+Anlotinib+ etoposide + carboplatin</arm_group_label>
    <arm_group_label>TQB2450（blank）+Anlotinib+ etoposide + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide is a cell cycle-specific antitumor drug</description>
    <arm_group_label>TQB2450+Anlotinib+ etoposide + carboplatin</arm_group_label>
    <arm_group_label>TQB2450（blank）+Anlotinib+ etoposide + carboplatin</arm_group_label>
    <arm_group_label>TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is cell cycle nonspecific antitumor drug</description>
    <arm_group_label>TQB2450+Anlotinib+ etoposide + carboplatin</arm_group_label>
    <arm_group_label>TQB2450（blank）+Anlotinib+ etoposide + carboplatin</arm_group_label>
    <arm_group_label>TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450（blank）</intervention_name>
    <description>Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day</description>
    <arm_group_label>TQB2450（blank）+Anlotinib+ etoposide + carboplatin</arm_group_label>
    <arm_group_label>TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib（blank)</intervention_name>
    <description>Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
    <arm_group_label>TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Pathologically confirmed extensive small cell Lung cancer; 2. Has not received
             systematic treatment for extensive small cell lung cancer; 3. Has received
             radiotherapy and chemotherapy for limited stage SCLC must have received radical
             treatment, and has at least 6 months of no treatment interval from the last treatment
             to the diagnosis of extensive SCLC; 4. Has measurable lesion based on Response
             Evaluation Criteria in Solid Tumors (RECIST) version 1.1; 5. 18 and 75 years old;
             Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, life
             expectancy≥ 12 weeks; 6. Adequate organ system function; 7. Male or female subjects
             should agree to use an adequate method of contraception starting with the first dose
             of study therapy through 6 months after the last dose of study (such as intrauterine
             devices , contraceptives or condoms) ; No pregnant or breastfeeding women, and a
             negative pregnancy test are received within 7 days before the randomization; 8.
             Understood and signed an informed consent form.

        Exclusion Criteria:

          -  1. Has prior therapy with anlotinib, anti-programmed cell death (PD)-1, anti-PD-L1 or
             other immunotherapy against PD-1/PD-L1; 2. Has central nervous system metastasis
             and/or cancerous meningitis; 3. Has diagnosed and/or treated additional malignancy
             within 5 years prior to randomization. Exceptions include cured basal cell carcinoma
             of skin and carcinoma in situ of cervix; 4. Has multiple factors affecting oral
             medication, such as inability to swallow, post-gastrointestinal resection, chronic
             diarrhea and intestinal obstruction, etc; 5. Has uncontrollable pleural effusion,
             pericardial effusion, or ascites requiring recurrent drainage procedures; 6. Has
             spinal cord compression which was not cured or relieved through surgery and/or
             radiotherapy, or diagnosed spinal cord compression after treatment showed no clinical
             evidence of disease stabilization prior to randomization ≥1 week; 7. Imaging (CT or
             MRI) shows that tumor invades large blood vessels or the boundary with blood vessels
             is unclear; 8. Within 2 months prior to initial administration, subjects with evidence
             or history of bleeding tendency, regardless of severity; A history of hemoptysis
             (defined as blood bright red or 1/2 teaspoon) or an unhealed wound, ulcer, or fracture
             in the 2 weeks prior to initial administration; 9. Has adverse events caused by
             previous therapy except alopecia that did not recover to ≤ grade 1; 10.Has major
             surgical procedure、biopsy or obvious traumatic injury within 28 days before
             randomization; 11. Has arterial or venous thromboembolic events occurred within 6
             months, such as cerebrovascular accident including transient ischemic attack, deep
             vein thrombosis and pulmonary embolism; 12.Has drug abuse history that unable to
             abstain from or mental disorders; 13. Has any severe and/or uncontrolled disease; 14.
             Has vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first
             administration.; 15. Severe hypersensitivity occurs after administration of other
             monoclonal antibodies; 16. Active autoimmune diseases requiring systemic treatment
             occurred within 2 years prior to first administration ; 17. Immunosuppressive therapy
             with immunosuppressive agents or systemic or absorbable local hormones (dosage &gt; 10
             mg/day prednisone or other therapeutic hormones) is required for the purpose of
             immunosuppression, and is still in use for 2 weeks after the first administration; 18.
             Has participated in other anticancer drug clinical trials within 4 weeks; 19.
             According to the judgement of the researchers, there are other factors that may lead
             to the termination of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Cheng, doctor</last_name>
    <phone>0431-85873390</phone>
    <email>jl.cheng@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junbin Wang</last_name>
      <phone>0552-3074480</phone>
      <email>bbmcwjb@163.com</email>
    </contact>
    <investigator>
      <last_name>Junbin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anhui chest hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haohui Fang, Bachelor</last_name>
      <phone>0551-63615328</phone>
      <email>fanghh88@163.com</email>
    </contact>
    <investigator>
      <last_name>Haohui Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AnHui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kangsheng Gu, Doctor</last_name>
      <phone>0551-62923093</phone>
      <email>13805692145@153.com</email>
    </contact>
    <investigator>
      <last_name>Kangsheng Gu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hui Zhao</last_name>
      <phone>0551-65997169</phone>
      <email>zhaohuichenxi@126.com</email>
    </contact>
    <investigator>
      <last_name>Hui Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing chest hospital，capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Baolan Li, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Baolan Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinhuo Lai</last_name>
      <phone>0591-86218442</phone>
      <email>ljh2252@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jinhuo Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wu Zhuang</last_name>
      <phone>0591-62002062</phone>
      <email>zhuangwu2008@126.com</email>
    </contact>
    <investigator>
      <last_name>Wu Zhuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yixin Wan</last_name>
      <phone>0931-8942347</phone>
      <email>101937415@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yixin Wan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junnian Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial Cancer Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shihong Wei</last_name>
      <phone>0931-2302833</phone>
      <email>weishihong100@163.com</email>
    </contact>
    <investigator>
      <last_name>Shihong Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianxing He</last_name>
      <phone>020-83062807</phone>
      <email>hejx@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Jianxing He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fiest Affiliated Hospital of Guanghzou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lizhu Lin</last_name>
      <phone>020-36596356</phone>
      <email>lizhulin903@21cn.com</email>
    </contact>
    <investigator>
      <last_name>Lizhu Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shubin Wang</last_name>
      <phone>0755-83923333-2501</phone>
      <email>Wangshubin2013@163.com</email>
    </contact>
    <investigator>
      <last_name>Shubin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangdong Medical University</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hualin Chen</last_name>
      <phone>0759-2387458</phone>
      <email>3549509@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hualin Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qitao Yu</last_name>
      <phone>0771-12580</phone>
      <email>yqt178@163.com</email>
    </contact>
    <investigator>
      <last_name>Qitao Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guizhou Provincial people's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550002</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xianwei Ye</last_name>
      <phone>0851-8560232</phone>
      <email>yxw1205@163.com</email>
    </contact>
    <investigator>
      <last_name>Xianwei Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Hainan Medical University</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570100</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haifeng Lin</last_name>
      <phone>0898-66809162</phone>
      <email>13322060949@163.com</email>
    </contact>
    <investigator>
      <last_name>Haifeng Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shijiazhuang First Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Zhang</last_name>
      <phone>0311-86907259</phone>
      <email>13315978336@163.com</email>
    </contact>
    <investigator>
      <last_name>Yan Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Chest Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050048</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Zhao</last_name>
      <phone>0311-86911008</phone>
      <email>z-mxk1067@126.com</email>
    </contact>
    <investigator>
      <last_name>Min Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Yu</last_name>
      <phone>0451-86298303</phone>
      <email>gpyuyan@163.com</email>
    </contact>
    <investigator>
      <last_name>Yan Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qiming Wang</last_name>
      <phone>0371-65588421</phone>
      <email>qimingwang1006@126.com</email>
    </contact>
    <investigator>
      <last_name>Qiming Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinzhou Central Hospital</name>
      <address>
        <city>Jinzhou</city>
        <state>Hubei</state>
        <zip>434020</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanhua Xu</last_name>
      <phone>0716-8881888</phone>
      <email>xuyanhua339@126.com</email>
    </contact>
    <investigator>
      <last_name>Yanhua Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianhua Chen</last_name>
      <phone>0731-89762220</phone>
      <email>cjh_1000@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianhua Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Lianyungang</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiashu Li</last_name>
      <phone>025-85605031</phone>
      <email>ljssm1118@sina.com</email>
    </contact>
    <investigator>
      <last_name>Jiashu Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ying Cheng, Doctor</last_name>
      <phone>0431-85873390</phone>
      <email>jl.cheng@163.com</email>
    </contact>
    <investigator>
      <last_name>Ying Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Zhang</last_name>
      <phone>0411-84671291</phone>
      <email>zydl@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yang Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>January 18, 2020</last_update_submitted>
  <last_update_submitted_qc>January 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

